Mankind Pharma Share Price: Motilal Oswal ka Bada Target! Stock **₹2,640** tak ja sakta hai?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Mankind Pharma Share Price: Motilal Oswal ka Bada Target! Stock **₹2,640** tak ja sakta hai?
Overview

Brokers ne Mankind Pharma par bharosa dikhaya hai! Motilal Oswal ne 'BUY' rating continue karte hue stock ka target **₹2,640** set kiya hai. Company ka domestic formulation business acche se recover kar raha hai aur Indian Pharma Index ko bhi outshine kar raha hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Domestic Business Ka Toofani Comeback!

Mankind Pharma ka domestic formulation business ekdum se zinda ho gaya hai. March 2026 tak is segment mein 11.5% ka year-on-year growth record hua hai. Yeh performance Indian Pharmaceutical Index (IPM) ke 10.6% growth se 1.1 percentage points aage hai, jo kaafi impressive hai.

Kaise Ho Raha Hai Yeh Sab?

Recovery khaas kar chronic therapies mein dikh rahi hai. Cardiac treatments mein company ne around 20% growth aur anti-diabetic drugs mein 12.6% growth dikhaya hai. Isse lagta hai ki company apne business ko better manage kar rahi hai aur restructuring ke baad execution bhi smooth ho gaya hai.

Aage Kya?

Motilal Oswal ke hisaab se, company abhi apne 12-month forward earnings ke 35 times par trade kar rahi hai. Brokerage ka maan na hai ki company ki growth story, strong domestic presence, aur recent acquisitions se fayda milega. Isi liye unhone BUY call maintain kiya hai aur target ₹2,640 rakha hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.